Table of contents

Diffuse large B-cell lymphoma (short version)

Date of document July 2022
This document is not the most recent version. Please view: Diffuses großzelliges B-Zell-Lymphom


Diffuse large B-cell lymphoma is the most common neoplasm of the lymphatic system. It originates from mature B cells and rapidly leads to death if left untreated. Rapidly progressive lymph node enlargement and/or extranodal manifestations as well as general symptoms (B-symptoms) are characteristic.

The individual prognosis can be estimated using the International Prognostic Index.

The therapeutic goal is curative. First-line therapy consists of 6-8 cycles of the R-CHOP protocol or, depending on the risk profile, R-CHOP-like protocols. In early stages in the absence of risk factors, a reduction of treatment cycles is possible. The role of radiation has not been definitively determined. Other unresolved issues such as prognosis- or response-driven therapy, the value of more intensive treatment protocols, or the efficacy of new agents are the subject of prospective clinical trials.

The cure rate of patients with diffuse large B-cell lymphoma is approximately 60-70%.


The current treatment algorithm is depicted in Figure 1.

Figure 1: Treatment algorithm in patients with diffuse large B-cell lymphoma 
curative treatment intent; non-curative treatment intent;
* Involved site radiotherapy should be considered for circumscribed PET positive residual lymphoma.

3[Kapitel nicht relevant]

4[Kapitel nicht relevant]

5[Kapitel nicht relevant]

6[Kapitel nicht relevant]

7[Kapitel nicht relevant]

8[Kapitel nicht relevant]

9[Kapitel nicht relevant]

10Active studies

11Systemic Therapy – Protocols

12Study results

13Certification Status

15Authors' Affiliations

Prof. Dr. med. Björn Chapuy
Charité Universitätsmedizin Berlin
Medizinische Klinik mit Schwerpunkt
Hämatologie und Onkologie
Hindenburgdamm 30
12200 Berlin
Prof. Dr. med. Bertram Glaß
HELIOS Klinikum Berlin-Buch
Klinik für Hämatologie, Onkologie und Tumorimmunologie
Schwanebecker Chaussee 50
13125 Berlin
Prim. Univ.-Prof. Dr. Felix Keil
3. Medizinischen Abteilung
Hämatologisch-Onkologisches Zentrum
Heinrich-Collin-Str. 30
A-1140 Wien
Prof. Dr. Wolfram Klapper
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Institut für Pathologie, Sektion für Hämatopathologie
Arnold-Heller-Str. 3, Haus 14
24105 Kiel
Prof. Dr. Georg Lenz
Universitätsklinikum Münster
Translationale Onkologie
Albert-Schweitzer-Campus 1, Gebäude D3
48149 Münster
Dr. med. Maike Nickelsen
Onkologie Lerchenfeld
Lerchenfeld 14
22081 Hamburg
Prof. Dr. med. Urban Novak
INSELSPITAL, Universitätsspital Bern
Klinik und Poliklinik für Medizinische Onkologie
CH-3010 Bern
Prof. Dr. med. Heinz Schmidberger
Universitätsmedizin Mainz
Klinik für Radioonkologie und Strahlentherapie
Langenbeckstr. 1
55131 Mainz
Prof. Dr. med. Clemens A. Schmitt
Kepler Universitätsklinikum
Klinik für Interne 3 - Schwerpunkt Hämatologie und Onkologie
Krankenhausstr. 9
A-4021 Linz


Conflicts of interest can be found in the full German version of the guideline.




Onkopedia-Leitlinien werden kontinuierlich an den Stand des Wissens angepasst. Die jeweils gültige Version, AGB und Nutzungsbedingungen finden Sie unter www.onkopedia.com.

Für die kommerzielle Nutzung wenden Sie sich bitte an onkopedia@dgho.de.

Onkopedia guidelines are continuously adapted to the state of knowledge. The currently valid version, terms of use and general terms and conditions can be found at onkopedia-guidelines.info.

For commercial use, please contact onkopedia@dgho.de.


Commenting has been disabled.